Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGAV | P06756 | 1/20 | 0.45 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30640436 | 1.00 | KMT2A (0.59) | KMT2AEPHX2CASP3ITGB3ITGAV | |
| SCHEMBL3177417 | 0.91 | KMT2A (0.62) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL30422053 | 0.89 | KMT2A (0.56) | KMT2AEPHX2CASP3ITGB3ITGAV | |
| SCHEMBL525396 | 0.89 | KMT2A (0.56) | KMT2AEPHX2CASP3ITGB3ITGAV | |
| SCHEMBL1921443 | 0.88 | KMT2A (0.50) | KMT2AEPHX2RORC | |
| SCHEMBL30570803 | 0.88 | KMT2A (0.63) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL18740102 | 0.88 | KMT2A (0.63) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL2631637 | 0.88 | KMT2A (0.63) | KMT2AEPHX2CASP3OPRD1 | |
| SCHEMBL29678978 | 0.87 | KMT2A (0.56) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL118108 | 0.87 | KMT2A (0.56) | KMT2AEPHX2CASP3FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2026-03-12 | — | — | US | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| CN-119431260-A | Targeting prostate specific membranes radiolabeled compounds for antigens | 省卫生服务机构 | 2025-02-14 | — | — | CN | disclosed |
| CN-114401947-B | Targeting prostate specific membranes radiolabeled compounds for antigens | 省卫生服务机构 | 2024-11-29 | — | — | CN | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| WO-2024059472-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230393140-A1 | BINDING ASSAYS INVOLVING A PLURALITY OF SYNTHETIC COMPOUNDS, TARGETS, AND COUNTER TARGETS | SRI INTERNATIONAL (US) | 2023-12-07 | — | — | US | disclosed |
| WO-2023225661-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-4229211-A1 | BINDING ASSAYS INVOLVING A PLURALITY OF SYNTHETIC COMPOUNDS, TARGETS, AND COUNTER TARGETS | SRI International (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2007117404-A2 | METHODS AND MATERIALS FOR PREPARING ORGANIC COMPOUNDS FROM PRIMARY AMINES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. | 2007-01-18 | — | — | US | disclosed |
| WO-2007005491-A1 | HYDRAZIDE CONJUGATES AS IMAGING AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-01-11 | — | — | WO | disclosed |
| US-6878743-B2 | Small molecule inhibitors of caspases | SUNESIS PHARMACEUTICALS, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20030114447-A1 | Small molecule inhibitors of caspases | SUNESIS PHARMACEUTICALS, INC. | 2003-06-19 | — | — | US | disclosed |
| WO-2003024955-A2 | SMALL MOLECULE INHIBITORS OF CASPASES | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | KMT2A 4690/4885EPHX2 4299/4885CASP3 795/4885 |
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | CA14, CA13, CA1 | KMT2A 2223/4885EPHX2 675/4885CASP3 533/4885 |
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | KMT2A 1528/4885EPHX2 3786/4885CASP3 1567/4885 |
| US-20030114447-A1 | Small molecule inhibitors of caspases | CASP1, CASP9, CASP2 | KMT2A 4436/4885EPHX2 2451/4885CASP3 5/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | KMT2A 4690/4885EPHX2 4299/4885CASP3 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.